Surgery Partners Delivers Impressive Q3 2025 Results
Surgery Partners, Inc. (NASDAQ: SGRY) has declared noteworthy achievements in its financial performance for the third quarter. This leading short-stay surgical facility operator reported a revenue increase of 6.6% compared to the previous year, amounting to $821.5 million. The positive trend reflects its resilience and dedication to enhancing surgical care.
Financial Highlights
During the third quarter of 2025, same-facility revenues rose by 6.3%. Surgical cases saw a modest growth of 2.1%, with same-facility cases increasing by 3.4%. Moreover, despite facing a net loss of $22.7 million, adjusted EBITDA climbed to $136.4 million, reflecting a year-over-year hike of 6.1%.
Revised Financial Guidance for 2025
In light of recent performances, Management now forecasts full-year 2025 revenue between $3.275 billion and $3.30 billion, with adjusted EBITDA projected from $535 million to $540 million. This prudent revision underscores the company's commitment to maintaining operational agility as it navigates challenges in the healthcare landscape.
Leadership Insights
Eric Evans, Chief Executive Officer, conveyed pride in the company's ongoing growth trajectory. He emphasized commitment to operational excellence and capital deployment strategies aimed at optimizing the performance of the Surgery Partners portfolio. The CEO also mentioned ongoing assessments of merger and acquisition opportunities to further enhance value.
Strategic Financial Management
Dave Doherty, Chief Financial Officer, stated that the third quarter's performance reflects the robustness of their business model, despite facing softer-than-anticipated volume and payor mix trends. The CFO reassured stakeholders about the company’s financial health, backed by $203.4 million in cash and a borrowing capacity of $405.9 million.
Year-to-Date Performance
For the first nine months of 2025, Surgery Partners achieved revenues of $2,423.7 million, marking a 7.7% increase from the previous year. The company’s operational efficiency is evident, with an increase in year-to-date adjusted EBITDA reaching $369.3 million.
Future Outlook
Going forward, Surgery Partners remains focused on fostering strategic partnerships and optimizing its operations to sustain growth. The company is well-positioned in the healthcare sector, continuously exploring opportunities to enhance its service offerings and market presence.
Frequently Asked Questions
What is the latest financial performance of Surgery Partners?
In Q3 2025, Surgery Partners recorded $821.5 million in revenue, marking a 6.6% increase from the prior year.
How does the leadership view the company's performance?
CEO Eric Evans emphasizes growth and operational excellence, highlighting successes in navigating challenges.
What are the projected figures for Surgery Partners in 2025?
The company expects revenues between $3.275 billion and $3.30 billion, with adjusted EBITDA forecasted at $535 million to $540 million.
What are the key drivers of revenue growth?
Strength in orthopedic procedures significantly contributed to the company’s revenue growth during the quarter.
How financially robust is Surgery Partners as of now?
Surgery Partners has strong liquidity with $203.4 million in cash and an available borrowing capacity of $405.9 million.
